Sanofi

SanofiSanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi Genzyme focuses on developing specialty treatments for debilitating diseases that are often difficult to diagnose and treat, providing hope to patients and their families.

www.sanofi.com

Filters
List of articles in category Sanofi
Title Published Date
Sanofi intends to sell its equity investment in Regeneron; confirms no change to ongoing collaboration 26 May 2020
Sanofi to donate 100 million doses of hydroxychloroquine across 50 countries 14 April 2020
First patient outside U.S. treated in global Kevzara® (sarilumab) clinical trial program for patients with severe COVID-19 02 April 2020
Sanofi completes acquisition of Synthorx, Inc. 29 January 2020
Educational campaign helps teens and their caregivers tackle the everyday challenges of living with moderate-to-severe atopic dermatitis 18 September 2019
Sanofi and Google to develop new healthcare Innovation Lab 27 June 2019
Sanofi builds focus on rare blood disorders and cancers 29 November 2018
Sanofi completes divestiture of Zentiva to Advent 03 October 2018
Sanofi and REVOLUTION Medicines launch global partnership to develop potential first-in-class targeted treatments for multiple cancers 23 July 2018
Sanofi and Ablynx announce the successful results of the initial tender offer period 14 May 2018
Sanofi to acquire Ablynx for €3.9 Billion 29 January 2018
Sanofi and Regeneron to accelerate and expand investment for cemiplimab and dupilumab development programs 15 January 2018
Sanofi and Regeneron announce approval of Dupixent® (dupilumab) to treat adult patients with moderate-to-severe atopic dermatitis in the European Union 29 September 2017
Sanofi and Regeneron announce approval of Kevzara® (sarilumab) to treat adult patients with moderately to severely active rheumatoid arthritis in the European Union 28 June 2017
Sanofi and Lead Pharma to develop treatments for autoimmune diseases 18 February 2015
Curie-Cancer and Sanofi cooperate in research on ovarian cancer 20 June 2013
Sanofi strengthens its French-German partnership 16 April 2013
Once-daily Lyxumia® (lixisenatide) approved for treatment of type 2 diabetes 04 February 2013
Sanofi provides information on the adaptation of its activities in France through 2015 25 September 2012
Sanofi and the Institut Pasteur create four prestigious awards 27 February 2012